Sun Pharma Q2FY26 net profit up 2.6%, eyes solar and renewable expansion

Sun Pharmaceutical Industries Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Consolidated Q2FY26 sales reached Rs. 144,052 million, an 8.6% year-over-year growth, with net profit rising 2.6% to Rs. 31,180 million. For the half-year, consolidated sales grew 9.3% to Rs. 281,913 million. The board also approved an alteration to the Memorandum of Association to incorporate an enabling clause for setting up captive solar, renewable, and other power plants, including the sale of surplus power to the grid.

Key drivers for growth included India formulations, up 11% to Rs. 47,348 million, and global innovative medicines, up 16.4% to $333 million, which surpassed generics sales for the first time this quarter. R&D investment for Q2FY26 was Rs. 7,827 million, or 5.4% of sales. The company confirmed an investor call audio recording is available, following its earnings call on November 5, 2025.